Larissa Hope was 17. She’d just landed a role on Skins. The fame hit her hard, digging up trauma she’d buried for years.
Antidepressants did nothing.
So she took a clinical dose of psilocybin.
It wasn’t a party trick. It was medicine. She wept uncontrollably, overwhelmed by a sudden, startling sensation of safety. “I’m home,” she kept saying.
Two decades later, she credits that single experience—and the therapy that followed—for pulling her back from suicidal thoughts.
Not everyone has a happy ending.
Take Jules Evans. A university researcher today, but at 18 he was just a kid experimenting with LSD. The result was horror. He became delusional, convinced the world was judging him. He felt his mind breaking in real time. Terrified. Broken.
Which story is true?
Maybe both.
A flood of new studies suggests psychedelics might actually work. For depression, PTSD, OCD, even gambling addiction. The science is shifting, but slowly. The UK’s medicines regulator is watching the data closely, specifically waiting for results from a major trial by Compass Pathways due this year.
Until then, the law is strict. Using these substances outside of authorized trials is illegal. Period.
But the old rules feel increasingly out of sync with the new reality.
“We desperately need more treatments… these have the potential to work quicker.”
— Prof Oliver Howes, Royal College of Psychiatrists
Prof Howes sees hope. Really quick-acting hope. Conventional antidepressants take weeks to engage. Psilocybin? It might rewire the relevant neural pathways in minutes. Imagine stopping a depression spiral before it starts, not weeks later when you’re already drowning.
But hope isn’t data.
Dr David Nutt at Imperial College London sparked this revival in the 2010ns. His early trials showed psilocybin matching traditional meds with fewer side effects. The speed is the kicker. It’s about breaking the loop. Like Pavlov’s dog, an addict learns to associate a setting or feeling with their fix. Nutt believes psychedelics can shatter that association.
Is it magic? Or just better biology?
We don’t know yet.
The caution is well-founded. The Royal College of Psychiatrists warned about risks in 2025. And for good reason. A survey by Challenging Psychedelic Experiences paints a darker picture:
– 52% of regular users had intensely challenging trips.
– 39% called those trips among the worst of their lives.
– 8.9% felt impaired for more than a day afterward.
– 6.7% considered harming themselves or others.
Evans sees these stats and feels relief. Doctors need to understand how bad it can get before declaring anything “safe.” Recovery takes time. Months. Sometimes years.
Yet Nutt calls the current red tape a “moral failing.” People are dying while bureaucracy grinds research to a halt. He wants NHS access for all, not just those with money.
Ketamine already has a medical foothold in the UK. But psilocybin? LSD? DMT? Still banned under Schedule 1 drugs, classified as having no medical value. A classification many researchers say is outdated nonsense.
The government is nibbling at the edge of reform. Some universities and NHS sites are getting pilot exemptions. But change is glacial.
“If psychedelic therapies prove safe… I would hope to see them via the NHS.” — Prof Nutt
He wants them for the public, not the privileged. But will the regulator listen?
The Compass Pathways phase three trials might force a conversation. Or they might confirm the skeptics’ doubts. The line between miracle cure and dangerous hallucination is thin, drawn in individual biology.
Larissa Hope knows what peace feels like now. For her, death stopped being the only exit. Her nervous system remembered how to calm down.
But millions haven’t found their version of “home.” The science promises a door. The law is still holding the handle.
Whether it opens… depends on who holds the key next year.
